SLP

Simulations Plus (SLP) reported fiscal Q3 adjusted net income late Thursday of $0.30 per diluted sha

RESEARCH TRIANGLE PARK, N.C. (AP) — RESEARCH TRIANGLE PARK, N.C. (AP) — Simulations Plus Inc. (SLP) on Thursday reported net income of $3.6 million in its fiscal third quarter. On a per-share basis, the Research Triangle Park, North Carolina-based company said it had net income of 18 cents. Earnings, adjusted for non-recurring costs, were 30 cents per share. The maker of software used in pharmaceutical research posted revenue of $21.9 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on SLP at https://www.zacks.com/ap/SLP

RESEARCH TRIANGLE PARK, N.C., July 09, 2026--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today reported financial results for its third quarter fiscal 2026, ended May 31, 2026. Third Quarter 2026 Financial Highlights (as compared to third quarter 2025) Total revenue increased 7% to $21.9 million Software revenue was flat at $12.6 million, representing 58% of total revenue Services revenue increased 20% to $9.3 million, representing 42% of total revenue Gross profit was $15.1 million and gross margin was 69%, compared to $13.0 million and 64% Net income of $3.6 million and diluted earnings per share of $0.18, compared to net loss of $67.3 million and diluted losses per share of $3.35 Adjusted EBITDA of $7.9 million, representing 36% of total revenue, compared to $7.4 million, representing 37% of total revenue Adjusted net income of $6.1 million and adjusted diluted EPS of $0.30 compared to adjusted net income of $9.0 million and adjusted diluted EPS of $0.45 Nine Months 2026 Financial Highlights (as compared to nine months 2025) Total revenue increased 5% to $64.6 million Software revenue decreased 2% to $36.1 million, representing 56% of total revenue Services revenue increased 14% to $28.5 million, representing 44% of total revenue Gross profit was $42.2 million and gross margin was 65%, compared to $36.4 million and 59% Net income of $8.8 million and diluted earnings per share of $0.43, compared to net loss of $64.0 million and diluted losses per share of $3.19 Adjusted EBITDA of $20.2 million, representing 31% of total revenue, compared to $18.5 million, representing 30% of total revenue Adjusted net income of $15.7 million and adjusted diluted EPS of $0.78, compared to $18.7 million and adjusted diluted EPS of $0.93 Management Commentary "We delivered solid third quarter results, with revenue increasing 7%, highlighted by strength in our services revenue, which grew 20%, while software revenue was flat year over year," said Shawn O'Connor, Chief Executive Officer of Simulations Plus. "Our performance reflects the resilience of our business model and the value our solutions provide to clients across the drug development lifecycle." "Subsequent to quarter end, on June 15, 2026, we entered into a definiti...

Celebrations may be in order for SLP Resources Berhad (KLSE:SLP) shareholders, with the covering analyst delivering a significant upgrade to their statutory estimates for the company. The analyst greatly increased their revenue estimates, suggesting a stark improvement in business fundamentals. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. After the upgrade, the one analyst covering SLP Resources Berhad is now predicting revenues of RM194m in 2026. If met, this would reflect a sizeable 34% improvement in sales compared to the last 12 months. Per-share earnings are expected to bounce 160% to RM0.064. Previously, the analyst had been modelling revenues of RM166m and earnings per share (EPS) of RM0.046 in 2026. So we can see there's been a pretty clear increase in analyst sentiment in recent times, with both revenues and earnings per share receiving a decent lift in the latest estimates. Check out our latest analysis for SLP Resources Berhad One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. One thing stands out from these estimates, which is that SLP Resources Berhad is forecast to grow faster in the future than it has in the past, with revenues expected to display 34% annualised growth until the end of 2026. If achieved, this would be a much better result than the 2.1% annual decline over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in the industry are forecast to see their revenue grow 11% per year. So it looks like SLP Resources Berhad is expected to grow faster than its competitors, at least for a while. The biggest takeaway for us from these new estimates is that the analyst upgraded their earnings per share estimates, with improved earnings power expected for this year. Fortunately, the analyst also upgraded their revenue estimates, and our data indicates sales are expected to perform better than the wider market. With a serious upgrade to expectations, it might be time to take another look at SLP Resources Berhad. These earnings upgrades look like a sterling endorsement, but before diving in - you should know that we've spotted 2 potential flag with SLP Resources Berhad, including the risk of cutting its dividend. You ca...

Badger Meter, Inc. BMI reported earnings per share (EPS) of 93 cents for first-quarter 2026, which missed the Zacks Consensus Estimate by 22.5%. The bottom line compared unfavorably with the year-ago quarter’s EPS of $1.30. Quarterly net sales were $202.3 million, down 9% from $222.2 million in the year-ago quarter due to delayed project deployments and weaker-than-expected short-cycle order activity. The Zacks Consensus Estimate was pegged at $230.1 million. Management highlighted that the year-over-year decline in revenue and the associated operating leverage primarily stemmed from fluctuations in project timing and short-cycle customer ordering patterns, rather than any deterioration in underlying demand, competitive positioning, or long-term market drivers. The company maintains confidence in its outlook, supported by a solid pipeline of awarded projects set to commence in the second half of 2026 and a robust multi-year opportunity funnel. Amid this near-term variability, the company remains focused on executing its long-term strategy. As part of this effort, it has announced a definitive agreement to acquire UDlive, a U.K.-based provider of hardware-enabled software solutions for sewer line monitoring. The addition of UDlive enhances the SmartCover platform by broadening sewer line monitoring capabilities across diverse use cases, network conditions and geographies. These solutions strengthen the company’s leadership in a growing global market driven by aging infrastructure, evolving regulatory requirements and climate-related challenges. Furthermore, UDlive bolsters the BlueEdge suite, enabling utilities to gain deeper, actionable insights across the water cycle, while expanding the company’s presence and supporting the growth of higher-margin, recurring software revenue over time. Image Source: Zacks Investment Research BMI’s shares fell 24% on Friday, closing at $115.54 in response to the weaker-than-expected results. In the past six months, shares have lost 34.5% against the Zacks Instruments-Control industry’s growth of 4.9%. In the quarter under review, utility water sales decreased 10% year over year. The decline was due to project timing variability and softer short-cycle municipal customer orders, partially offset by strength in SaaS, SmartCover, water quality and network monitoring solutions. Flow instrumentation sales decreased 4% year over y...

Q2 revenue of $24.3 million (+8% YoY) topped management guidance, with adjusted EBITDA of $8.7 million (36% margin) and adjusted EPS $0.35; full-year revenue guidance remains $79–$82 million while adjusted diluted EPS was updated to $0.75–$0.85 reflecting a higher expected effective tax rate (23–25%). Operational momentum included software-led growth (software +9%, services +8%), a services backlog up 18% to $24 million, expanded gross margin to 66%, 297 commercial clients, and a quarterly renewal rate of 91%. AI and pharma collaborations are being embedded across the product roadmap and involve three large pharma partners, but management does not expect meaningful financial contribution from these programs until fiscal 2027. Interested in Simulations Plus, Inc.? Here are five stocks we like better. 52-Week Lows? No Problem for 3 Stocks With Big Upside Potential Simulations Plus (NASDAQ:SLP) reported second-quarter fiscal 2026 revenue of $24.3 million, exceeding the top-line guidance management provided last quarter, as the company delivered growth in both its software and services segments. Chief Executive Officer Sean O’Connor said adjusted EBITDA was $8.7 million, representing a 36% margin, and adjusted diluted EPS was $0.35, which he said was “in line with our internal expectations.” O’Connor said the company continues to see “encouraging market conditions globally,” pointing to factors including “ongoing most favored nation pricing agreements, easing tariff concerns, and a more supportive funding environment for our customers.” He also noted that guidance around new approach methodologies (NAMs) issued late last year was “further clarified with an additional update last month.” → This New ETF Aims to Capitalize on Surging AI Memory Chip Demand Simulations Plus Stock Drops 15% Despite EPS Beat Against that backdrop, O’Connor said Simulations Plus is seeing “a pickup in client spending,” which he said is reflected in “solid software renewal rates, increased new logo activity, and strength in service bookings.” While he characterized the first half as strong, O’Connor also emphasized caution about the operating environment during the question-and-answer portion of the call, describing it as “fragile” given macro and industry uncertainty. Chief Financial Officer Will Frederick said total revenue increased 8% year over year to $24.3 million. Software revenue...

Simulations Plus (SLP) reported fiscal Q2 adjusted earnings late Thursday of $0.35 per diluted share

Simulations Plus, Inc. SLP reported second-quarter fiscal 2026 adjusted earnings of 35 cents per share, surpassing the Zacks Consensus Estimate by 29%. The bottom line also compared favorably with the prior-year quarter’s 31 cents. Simulations Plus reported quarterly revenue of $24.3 million, marking an 8% year-over-year increase. This growth reflects continued demand for its core offerings, especially in drug discovery and development. The software segment remains the backbone of the company’s business model. Growth was driven by strong adoption of discovery and development solutions — areas where AI and modeling tools are becoming increasingly indispensable in biopharma workflows. However, SLP noted a decline in clinical operations software, which appears to be a structural shift rather than a temporary dip. The company continues to see strong momentum in new client acquisition (logo additions) alongside ongoing upselling efforts, contributing to an 18% increase in backlog and strong visibility into future revenues. On the macro front, management highlighted an improving funding environment for biopharma clients, easing tariff pressures and the growing adoption of new approach methodologies. These factors are driving higher client activity, as reflected in robust renewals and bookings. The company’s ability to grow both software and services while expanding margins suggests a healthy, scalable business model. In response to the results, SLP’s shares climbed 18% in pre-market today. Simulations Plus, Inc. price-consensus-eps-surprise-chart | Simulations Plus, Inc. Quote Fiscal second-quarter revenues from Software (60% of total quarterly revenues) rose 9% year over year to $14.6 million. Software revenue was led by Development products, mainly GastroPlus and MonolixSuite, which contributed 78%, while Discovery products, primarily ADMET Predictor, accounted for 19%, and Clinical Ops products, led by Proficiency, made up the remaining 3%. SLP ended the quarter with 297 commercial clients, generating average revenue of $124,000 per client and an 91% renewal rate. SLP’s top 25 customers account for roughly 46% of its total software revenue, with this group remaining highly stable, reflected in 100% logo retention and gross revenue retention exceeding 90%. Services’ revenues (40%) improved 8% to $9.7 million. For the quarter, development services (biosimulation)...

RESEARCH TRIANGLE PARK, N.C. (AP) — RESEARCH TRIANGLE PARK, N.C. (AP) — Simulations Plus Inc. (SLP) on Thursday reported earnings of $4.5 million in its fiscal second quarter. The Research Triangle Park, North Carolina-based company said it had profit of 22 cents per share. Earnings, adjusted for one-time gains and costs, were 35 cents per share. The maker of software used in pharmaceutical research posted revenue of $24.3 million in the period, which topped Street forecasts. Three analysts surveyed by Zacks expected $21.4 million. Simulations Plus expects full-year earnings in the range of 75 cents to 85 cents per share, with revenue in the range of $79 million to $82 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on SLP at https://www.zacks.com/ap/SLP

Simulations Plus (SLP) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.31 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +29.63%. A quarter ago, it was expected that this maker of software used in pharmaceutical research would post earnings of $0.18 per share when it actually produced earnings of $0.13, delivering a surprise of -27.78%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Simulations Plus, which belongs to the Zacks Computer - Software industry, posted revenues of $24.29 million for the quarter ended February 2026, surpassing the Zacks Consensus Estimate by 13.51%. This compares to year-ago revenues of $22.43 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Simulations Plus shares have lost about 28.7% since the beginning of the year versus the S&P 500's decline of 0.9%. While Simulations Plus has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Simulations Plus was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near futur...

Revenue grew 8% with increases in both software and services RESEARCH TRIANGLE PARK, N.C., April 09, 2026--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today reported financial results for its second quarter fiscal 2026, ended February 28, 2026. Second Quarter 2026 Financial Highlights (as compared to second quarter 2025) Total revenue increased 8% to $24.3 million Software revenue increased 9% to $14.6 million, representing 60% of total revenue Services revenue increased 8% to $9.7 million, representing 40% of total revenue Gross profit was $16.1 million and gross margin was 66%, compared to $13.1 million and 59% Net income of $4.5 million and diluted earnings per share of $0.22, compared to net income of $3.1 million and diluted EPS of $0.15 Adjusted EBITDA of $8.7 million, representing 36% of total revenue, compared to $6.6 million, representing 29% of total revenue Adjusted net income of $7.0 million and adjusted diluted EPS of $0.35 compared to adjusted net income of $6.2 million and adjusted diluted EPS of $0.31 Six Months 2026 Financial Highlights (as compared to six months 2025) Total revenue increased 3% to $42.7 million Software revenue decreased 3% to $23.5 million, representing 55% of total revenue Services revenue increased 12% to $19.2 million, representing 45% of total revenue Gross profit was $27.0 million and gross margin was 63%, compared to $23.3 million and 56% Net income of $5.2 million and diluted earnings per share of $0.26, compared to net income of $3.3 million and diluted EPS of $0.16 Adjusted EBITDA of $12.3 million, representing 29% of total revenue, compared to $11.1 million, representing 27% of total revenue Adjusted net income of $9.6 million and adjusted diluted EPS of $0.48, approximately equivalent to the same period last year Management Commentary "We delivered solid second quarter results, with revenue increasing by 8%," said Shawn O’Connor, CEO of Simulations Plus. "Software growth was driven by strong performance in discovery and development solutions, partially offset by an anticipated decline in clinical operations software. We also saw continued success with new logo additions and client upsells. Services revenue growth was primarily driven by development solutions a...

This article first appeared on GuruFocus. Revenue: $24.3 million, an 8% increase. Adjusted EBITDA: $8.7 million, reflecting a 36% margin. Adjusted Diluted EPS: $0.35. Software Revenue: Increased 9%, representing 60% of total revenue. Services Revenue: Increased 8%, representing 40% of total revenue. Discovery Revenue: Increased 19% for the quarter. Development Revenue: Increased 12% for the quarter. Clinical Operations Revenue: Declined 54% for the quarter. Gross Margin: Total gross margin of 66%; Software gross margin of 89%; Services gross margin of 33%. Cash and Short-term Investments: $41.8 million. Effective Tax Rate: 23% for the quarter. Guidance for Fiscal 2026: Total revenue between $79 million to $82 million; Adjusted diluted EPS between $0.75 to $0.85. Warning! GuruFocus has detected 6 Warning Signs with SLP. Is SLP fairly valued? Test your thesis with our free DCF calculator. Release Date: April 09, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Simulations Plus Inc (NASDAQ:SLP) exceeded top-line guidance with $24.3 million in revenue for the second quarter, showing growth in both Software and Service segments. The company reported an adjusted EBITDA of $8.7 million, reflecting a strong 36% margin. Simulations Plus Inc (NASDAQ:SLP) has strategic collaboration programs with three large pharmaceutical companies to advance AI workflows, indicating strong industry partnerships. The company maintains a high software renewal rate of 91% for the quarter, demonstrating customer loyalty and satisfaction. Simulations Plus Inc (NASDAQ:SLP) ended the quarter with a robust cash position of $41.8 million and no debt, indicating strong financial health. Clinical operations revenue declined significantly by 54% for the quarter and 58% for the trailing 12-month period. The company experienced a decline in software renewal rates, particularly among smaller biopharma and precommercial biotech clients. Simulations Plus Inc (NASDAQ:SLP) reported an increased effective tax rate of 23% compared to 12% last year, impacting net income. The company anticipates minimal AI monetization in fiscal year 2026, indicating that AI-related revenue contributions are still in the early stages. Despite strong performance, the company maintained cautious revenue guidance for fiscal 2026, reflecting uncertainty in the macro envi...